{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:57:33Z","timestamp":1789610253759,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1053\/j.seminoncol.2010.09.007","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T04:37:49Z","timestamp":1289450269000},"page":"499-507","source":"Crossref","is-referenced-by-count":208,"title":["The Emerging Toxicity Profiles of Anti\u2013CTLA-4 Antibodies Across Clinical Indications"],"prefix":"10.1053","volume":"37","author":[{"given":"Anna Maria","family":"Di Giacomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Biagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2010.09.007_bib1","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O' Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib3","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib4","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib6","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","volume":"142","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2010.09.007_bib8","first-page":"15s","article-title":"Hair depigmentation as an indicator of a durable response to CTLA-4 therapy","volume":"28","author":"Pavlick","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2007.07.022","article-title":"Intertriginous and follicular eruption to anticytotoxic T-lymphocyte antigen 4 monoclonal antibody","volume":"59","author":"Lim","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immun"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib11","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib12","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s10620-009-0839-8","article-title":"Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells","volume":"55","author":"Lord","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2010.09.007_bib13","first-page":"7s","article-title":"An analysis of the effectivenes of specific guidelines for management of ipilimumab-mediated diarrea\/colitis: prevention of intestinal perforation and\/or colectomy","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","article-title":"Ipilimumab: controversies in its development, utility and autoimmune adverse events","volume":"58","author":"Weber","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib15","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-ytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study","volume":"12","author":"Maker","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1677\/jme.0.0310021","article-title":"CTLA-4 and its role in autoimmune thyroid disease","volume":"31","author":"Chistiakov","year":"2003","journal-title":"J Mol Endocrinol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00002371-200411000-00008","article-title":"Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis","volume":"27","author":"Robinson","year":"2004","journal-title":"J Immunother"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1017\/S0317167100007939","article-title":"Autoimmune inflammatory myopathy after treatment with ipilimumab","volume":"36","author":"Hunter","year":"2009","journal-title":"Can J Neurol Sci"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","article-title":"Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody)","volume":"32","author":"Akhatari","year":"2009","journal-title":"J Immun"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib23","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00262-008-0627-x","article-title":"Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma","volume":"58","author":"Gordon","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/CJI.0b013e318193a206","article-title":"Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report","volume":"32","author":"Bhatia","year":"2009","journal-title":"J Immunother"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2010.09.007_bib25","first-page":"15s","article-title":"Phase 2 trial of ipilimumab (IPI) and paclitaxel\/carboplatin (P\/C) in first-line stage IIIb\/IV non-small cell lung cancer (NSCLC)","volume":"28","author":"Lynch","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2010.09.007_bib26","first-page":"15s","article-title":"Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC)","volume":"28","author":"Harzstark","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib27","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib28","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1158\/1078-0432.CCR-10-0505","article-title":"Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells","volume":"16","author":"Vonderheide","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2010.09.007_bib29","first-page":"15s","article-title":"Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (patients) with advanced non-small cell lung cancer (NSCLC)","volume":"27","author":"Zatloukal","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2010.09.007_bib30","first-page":"15s","article-title":"Phase I dose escalation trial of tremelimumab plus sunitinib in patients (patients) with metastatic renal cell carcinoma (mRCC)","volume":"27","author":"Gordon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib31","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib32","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","article-title":"Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma","volume":"16","author":"Ralph","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2010.09.007_bib33","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775410001612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775410001612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T18:27:42Z","timestamp":1544120862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775410001612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0093775410001612"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2010.09.007","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}